Single institution experience with peptide receptor radionuclide therapy (PRRT) in neuroendocrine tumors (NET).
Duan H, Ninatti G, Girod B, Ferri V, Kunz P, Fisher G, Moradi F, Davidzon G, Franc B, Iagaru A, Mari C. Single institution experience with peptide receptor radionuclide therapy (PRRT) in neuroendocrine tumors (NET). Journal Of Clinical Oncology 2020, 38: 623-623. DOI: 10.1200/jco.2020.38.4_suppl.623.Peer-Reviewed Original ResearchPeptide receptor radionuclide therapyNETTER-1 trialObjective response rateProgression-free survivalNETTER-1 studyReceptor radionuclide therapyNeuroendocrine tumorsCycles of PRRTRadionuclide therapyInterim overall survival analysisProgressive neuroendocrine tumorsLines of therapySingle institution experienceOnly side effectMidgut neuroendocrine tumorsTreatment of patientsCourse of treatmentOverall survival analysisPFS ratesMetastatic diseaseCurative treatmentInstitution experiencePatient cohortSide effectsVs. 18